November 9, 2011
Lab21 Wins Biomedical Project of the Year Award
Cambridge, UK – 29 November 2011 - Lab21 Limited, the global specialist in personalised medicine and clinical diagnostics, has won the prestigious BioNow Biomedical Project of the Year Award for its MycAssay product line.
The BioNow Biomedical Project of the Year Award recognises individuals or organisations who have demonstrated an innovative solution to a specific industry problem.
Lab21’s MycAssay Aspergillus and MycAssay Pneumocystis are the world’s first commercial PCR assays for pulmonary fungal infections. A recent evaluation of MycAssay Aspergillus has shown it to be a sensitive and specific molecular test for the diagnosis of invasive aspergillus, an infection that affects approximately 200,000 people globally each year.
Hayden Jeffreys, Divisional Director of Products, Lab21 said: “This award for the MycAssay product line recognises the importance of Lab21’s tests for Aspergillus and Pneumocystis, the first products in what is rapidly becoming a portfolio of real-time PCR tests for serious invasive fungal diseases We are pleased with the adoption of these assays into routine use, demonstrated by increasing sales into 14 countries.”
Graham Mullis, CEO Lab21 added: “This award recognises the hard work of Professor David Denning and all the employees of Myconostica Ltd, the specialist molecular diagnostic company we acquired earlier this year. I am delighted with the early progress Lab21 is making in commercialising the MycAssay products. “
For further information:
Hayden Jeffreys, Divisional Director - Products
t: +44 163 8554 238
For media and investor enquiries:
Nicole Yost/Gemma Howe
t: +44 (0)20 7457 2020
Lab21 is a global leader in personalised healthcare. It provides diagnostic products and services and supports blood bank screening, medical diagnostics and drug discovery. Lab21 customers include international healthcare providers, pharmaceutical and diagnostic companies. The Products division of Lab21 manufactures immunodiagnostic kits and reagents that are distributed internationally and is focused on infectious diseases for the blood-banking and clinical markets. Our clinical services operations has a growing test portfolio providing companion diagnostics and high technology molecular assays. Lab21's corporate offices are based in Cambridge, UK and South Carolina, with a GMP manufacturing site in Cambridge and other manufacturing facilities in Newmarket, Camberley and Bridport. The Company's investors include Excalibur, Nexus Medical Partners and Medicis Capital. Website: www.lab21.com